RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy

Adrian P Wiegmans, Mariska Miranda, Shu Wen Wen, Fares Al-Ejeh, Andreas Moller

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mechanisms including; increased expression of the target gene PARP1, increased expression or reversion mutation of BRCA1, or up-regulation of the compensatory homologous recombination protein RAD51. Indeed, RAD51 has been demonstrated to be an alternative synthetic lethal target in BRCA1-mutated cancers. To overcome selective pressure on DNA repair pathways, we examined new potential targets within TNBC that demonstrate synthetic lethality in association with RAD51 depletion. We confirmed complementary targets of PARP1/2 and DNA-PK as well as a new synthetic lethality combination with p38. p38 is considered a relevant target in breast cancer, as it has been implicated in resistance to chemotherapy, including tamoxifen. We show that the combination of targeting RAD51 and p38 inhibits cell proliferation both in vitro and in vivo, which was further enhanced by targeting of PARP1. Analysis of the molecular mechanisms revealed that depletion of RAD51 increased ERK1/2 and p38 signaling. Our results highlight a potential compensatory mechanism via p38 that limits DNA targeted therapy.

Original languageEnglish
Pages (from-to)60087-60100
Number of pages14
JournalOncotarget
Volume7
Issue number37
DOIs
Publication statusPublished - 2016
Externally publishedYes

Keywords

  • Kinome
  • P38MAP Kinase
  • RAD51
  • Targeted therapy
  • Triple negative breast cancer

Cite this

Wiegmans, Adrian P ; Miranda, Mariska ; Wen, Shu Wen ; Al-Ejeh, Fares ; Moller, Andreas. / RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. In: Oncotarget. 2016 ; Vol. 7, No. 37. pp. 60087-60100.
@article{9ae888a87f904338b030a5cc91dfca87,
title = "RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy",
abstract = "The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mechanisms including; increased expression of the target gene PARP1, increased expression or reversion mutation of BRCA1, or up-regulation of the compensatory homologous recombination protein RAD51. Indeed, RAD51 has been demonstrated to be an alternative synthetic lethal target in BRCA1-mutated cancers. To overcome selective pressure on DNA repair pathways, we examined new potential targets within TNBC that demonstrate synthetic lethality in association with RAD51 depletion. We confirmed complementary targets of PARP1/2 and DNA-PK as well as a new synthetic lethality combination with p38. p38 is considered a relevant target in breast cancer, as it has been implicated in resistance to chemotherapy, including tamoxifen. We show that the combination of targeting RAD51 and p38 inhibits cell proliferation both in vitro and in vivo, which was further enhanced by targeting of PARP1. Analysis of the molecular mechanisms revealed that depletion of RAD51 increased ERK1/2 and p38 signaling. Our results highlight a potential compensatory mechanism via p38 that limits DNA targeted therapy.",
keywords = "Kinome, P38MAP Kinase, RAD51, Targeted therapy, Triple negative breast cancer",
author = "Wiegmans, {Adrian P} and Mariska Miranda and Wen, {Shu Wen} and Fares Al-Ejeh and Andreas Moller",
year = "2016",
doi = "10.18632/oncotarget.11065",
language = "English",
volume = "7",
pages = "60087--60100",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. / Wiegmans, Adrian P; Miranda, Mariska; Wen, Shu Wen; Al-Ejeh, Fares; Moller, Andreas.

In: Oncotarget, Vol. 7, No. 37, 2016, p. 60087-60100.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy

AU - Wiegmans, Adrian P

AU - Miranda, Mariska

AU - Wen, Shu Wen

AU - Al-Ejeh, Fares

AU - Moller, Andreas

PY - 2016

Y1 - 2016

N2 - The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mechanisms including; increased expression of the target gene PARP1, increased expression or reversion mutation of BRCA1, or up-regulation of the compensatory homologous recombination protein RAD51. Indeed, RAD51 has been demonstrated to be an alternative synthetic lethal target in BRCA1-mutated cancers. To overcome selective pressure on DNA repair pathways, we examined new potential targets within TNBC that demonstrate synthetic lethality in association with RAD51 depletion. We confirmed complementary targets of PARP1/2 and DNA-PK as well as a new synthetic lethality combination with p38. p38 is considered a relevant target in breast cancer, as it has been implicated in resistance to chemotherapy, including tamoxifen. We show that the combination of targeting RAD51 and p38 inhibits cell proliferation both in vitro and in vivo, which was further enhanced by targeting of PARP1. Analysis of the molecular mechanisms revealed that depletion of RAD51 increased ERK1/2 and p38 signaling. Our results highlight a potential compensatory mechanism via p38 that limits DNA targeted therapy.

AB - The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mechanisms including; increased expression of the target gene PARP1, increased expression or reversion mutation of BRCA1, or up-regulation of the compensatory homologous recombination protein RAD51. Indeed, RAD51 has been demonstrated to be an alternative synthetic lethal target in BRCA1-mutated cancers. To overcome selective pressure on DNA repair pathways, we examined new potential targets within TNBC that demonstrate synthetic lethality in association with RAD51 depletion. We confirmed complementary targets of PARP1/2 and DNA-PK as well as a new synthetic lethality combination with p38. p38 is considered a relevant target in breast cancer, as it has been implicated in resistance to chemotherapy, including tamoxifen. We show that the combination of targeting RAD51 and p38 inhibits cell proliferation both in vitro and in vivo, which was further enhanced by targeting of PARP1. Analysis of the molecular mechanisms revealed that depletion of RAD51 increased ERK1/2 and p38 signaling. Our results highlight a potential compensatory mechanism via p38 that limits DNA targeted therapy.

KW - Kinome

KW - P38MAP Kinase

KW - RAD51

KW - Targeted therapy

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84991396133&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11065

DO - 10.18632/oncotarget.11065

M3 - Article

VL - 7

SP - 60087

EP - 60100

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -